Evidence map›Paper›PMID 37862318›Full record

ArticlePloS one2023

Time series forecasting of COVID-19 infections and deaths in Alpha and Delta variants using LSTM networks.

Farnaz Sheikhi, Zahra Kowsari

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Farnaz SheikhiFaculty of Computer Engineering, K. N. Toosi University of Technology, Tehran, Iran.ORCID 0000-0002-7695-6047
Zahra KowsariFaculty of Computer Engineering, K. N. Toosi University of Technology, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the beginning of the rapidly spreading COVID-19 pandemic, several mutations have occurred in the genetic sequence of the virus, resulting in emerging different variants of concern. These variants vary in transmissibility, severity of infections, and mortality rate. Designing models that are capable of predicting the future behavior of these variants in the societies can help decision makers and the healthcare system to design efficient health policies, and to be prepared with the sufficient medical devices and an adequate number of personnel to fight against this virus and the similar ones. Among variants of COVID-19, Alpha and Delta variants differ noticeably in the virus structures. In this paper, we study these variants in the geographical regions with different size, population densities, and social life styles. These regions include the country of Iran, the continent of Asia, and the whole world. We propose four deep learning models based on Long Short-Term Memory (LSTM), and examine their predictive power in forecasting the number of infections and deaths for the next three, next five, and next seven days in each variant. These models include Encoder Decoder LSTM (ED-LSTM), Bidirectional LSTM (Bi-LSTM), Convolutional LSTM (Conv-LSTM), and Gated Recurrent Unit (GRU). Performance of these models in predictions are evaluated using the root mean square error, mean absolute error, and mean absolute percentage error. Then, the Friedman test is applied to find the leading model for predictions in all conditions. The results show that ED-LSTM is generally the leading model for predicting the number of infections and deaths for both variants of Alpha and Delta, with the ability to forecast long time intervals ahead.

Indexed as

COVID-19ForecastingHumansPandemicsSARS-CoV-2Time Factors

Identifiers

PMID37862318
PMCPMC10588884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.